Biogenysis Inc. Announces a Collaboration with Khalpey AI Lab in using Artificial Intelligence (AI) for Unveiling Potential Biomarkers and Predicting the Onset or Prevention of Alzheimer's Disease.

July 21, 2023 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / July 21, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Biogenysis, Inc. ("BGEN"), a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today a partnership with Khalpey AI Lab to identify biomarkers for early onset Alzheimer's disease.Alzheimer's disease affects over 5.2 million Americans over the age of 65 and hundreds of...

Read more

Biovica achieves PLA code for Medicare

July 21, 2023 2:20 AM

UPPSALA, SE / ACCESSWIRE / July 21, 2023 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, today announces that the company has received a PLA code from the AMA (American Medical Association), an important milestone in the commercialization of DiviTum® TKa in the United States.The PLA code is a specific code for the DiviTum® TKa test issued by the AMA and enables payers and providers to...

Read more

Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Traumatic Brain Injuries

July 20, 2023 12:00 PM

NEW YORK, NY / ACCESSWIRE / July 20, 2023 / Qrons Inc. (OTCQB:QRON) announced today the signing of a License Agreement Term Sheet effective July 17, 2023 with Professors Benjamin Sredni & Michael Albeck of Bar Ilan University in Israel for an exclusive world-wide, perpetual license of their IP in Tellurium based compounds. The IP will be used together Qrons' IP created by Dr. Ido Merfeld, Qrons co-founder as part of a new research program to...

Read more

The Now Corporation (OTC: NWPN) Ignites the African Gold Industry with a Game-Changing Acquisition

July 20, 2023 9:00 AM

OAKLAND PARK, FL / ACCESSWIRE / July 20, 2023 / The Now Corporation (OTC PINK:NWPN) is thrilled to unveil its groundbreaking entry into the African gold industry through the strategic acquisition of Sunshine Minerals Ltd. LLC, a Wyoming-based powerhouse. Brace yourselves for an exhilarating journey as The Now Corporation revolutionizes the way gold is exported from Africa to the global market.Sunshine Minerals is no ordinary mineral company-it's...

Read more

Neptune Nanotechnologies Inc. Secures $1.8 Million Canadian Dollars in Successful Seed Stage Fund Raise

July 19, 2023 9:40 AM

MARKHAM, ON / ACCESSWIRE / July 19, 2023 / Neptune Nanotechnologies Inc., a pioneering company at the forefront of bio-nanotechnology innovation, is thrilled to announce the successful closure of its seed stage fundraising, securing a remarkable $1.8 million Canadian Dollars in funding. The financing round was led by the prominent Canadian venture capital firm China Canada Angel Alliance (CCAA), with strong participation from follow-on investors...

Read more

Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products

July 19, 2023 9:05 AM

More countries are banning e-cigarettes as novel oral products gain tractionKELOWNA, BC / ACCESSWIRE / July 19, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has been granted a strategically important new patent in the oral nicotine sector by the United States Patent and Trademark Office ("USPTO").US patent #11,700,875 Compositions and Methods...

Read more

Aqualung Therapeutics Receives FDA Clearance To Proceed With the P2A PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients

July 18, 2023 5:30 PM

Aqualung Therapeutics will initiate moderate/severe ARDS patient recruitment for U.S. and Australia hospital sites in August 2023.Aqualung appoints Jackson Streeter MD to their board of directors bringing expertise to Aqualung to support advancing of ALT-100 mAb as a novel therapeutic for inflammatory and fibrotic diseases (ARDS, radiation-induced lung fibrosis, pulmonary arterial hypertension)TUCSON, AZ and JUNO BEACH, FL / ACCESSWIRE / July...

Read more

Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring

July 18, 2023 9:15 AM

BOSTON, MA / ACCESSWIRE / July 18, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today provided a strategic update following recent events that have impacted its inhaled respiratory franchise, including AstraZeneca's discontinuation of enrollment of the Phase 2a study for...

Read more

Oxford Biomedica Implements Sapio Sciences' Electronic Laboratory Notebook

July 18, 2023 7:00 AM

Sapio's No-Code ELN to Provide Enhanced Collaboration, Unified Data Access, and Flexible Workflows to viral vector CDMO Oxford BiomedicaBALTIMORE, MD / ACCESSWIRE / July 18, 2023 / Oxford Biomedica (OXB), a quality and innovation-led viral vector CDMO, has implemented Sapio's Electronic Laboratory Notebook (ELN) as part of its digital transformation. The integration of Sapio's ELN is set to increase efficiency of completing tasks, and bolster...

Read more

Oxford Biomedica Implements Sapio Sciences' Electronic Laboratory Notebook

July 18, 2023 7:00 AM

Sapio's No-Code ELN to Provide Enhanced Collaboration, Unified Data Access, and Flexible Workflows to viral vector CDMO Oxford BiomedicaBALTIMORE, MD / ACCESSWIRE / July 18, 2023 / Oxford Biomedica (OXB), a quality and innovation-led viral vector CDMO, has implemented Sapio's Electronic Laboratory Notebook (ELN) as part of its digital transformation. The integration of Sapio's ELN is set to increase efficiency of completing tasks, and bolster...

Read more

Adolore Biotherapeutics Presents Encouraging Preclinical Data of Innovative Gene Therapy Approach to Chronic Pain at the 2023 American Society of Pain and Neuroscience (ASPN) Annual Conference

July 17, 2023 11:00 AM

Data demonstrate preclinical proof-of-concept for rdHSV-based CA8* gene therapy as a disease-modifying long-acting local anesthetic that has the potential to replace opioids in chronic osteoarthritis (OA) knee pain managementCompany continues to advance development of rdHSV-CA8* gene-therapy injected in the knee joint for chronic OA knee pain towards INDDELRAY BEACH, FL / ACCESSWIRE / July 17, 2023 / Adolore Biotherapeutics ("Adolore" or the...

Read more

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

July 14, 2023 9:00 AM

PHOENIX, AZ / ACCESSWIRE / July 14, 2023 / Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this type of manipulation has been associated with cancer treatments, innovative companies are applying the same principles to a wide variety of diseases. Part of the vanguard innovation that is taking place...

Read more

enVVeno Medical to Host Virtual KOL Event on July 18, 2023

July 14, 2023 8:05 AM

IRVINE, CA / ACCESSWIRE / July 14, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today reminded investors that it will host a virtual KOL event on Tuesday, July 18, 2023, at 3:00 PM ET. To register for the event, please click here. The KOL event will feature two principal investigators from the Company's ongoing SAVVE (Surgical...

Read more

Petros Pharmaceuticals Announces Capital Raise of $15 Million

July 13, 2023 4:30 PM

Provides Update on Progress Toward Over the Counter (non-prescription) Development of STENDRANEW YORK, NY / ACCESSWIRE / July 13, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or "the Company"), a pioneer in expanding consumer access to medication through the over the counter (OTC) pathway, today announces a $15 million private placement financing that will support its continued progress towards bringing its erectile dysfunction...

Read more

NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day

July 13, 2023 8:30 AM

CLEVELAND, OH / ACCESSWIRE / July 13, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its Chief Executive Officer Dr. Dwain K. Irvin will be participating in the National Brain Tumor Society's (NBTS) fifth annual Glioblastoma Awareness Day on July 19, 2023 in support of the fight against one of the fastest growing and aggressive brain...

Read more

First Patient Dosed in Psycheceutical's Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD

July 13, 2023 8:00 AM

Psycheceutical's clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder through the company's NeuroDirect™ delivery system.MIAMI, FL / ACCESSWIRE / July 13, 2023 / Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health...

Read more

50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis

July 12, 2023 9:00 AM

SEATTLE, WA / ACCESSWIRE / July 12, 2023 / One in eight women will be diagnosed with breast cancer during their lifetime. However, breast cancer does not affect all women in the same way, and individual physiology plays a huge factor. Women with dense breast tissue face a higher risk of developing breast cancer and being diagnosed with later-stage disease. Dense breast tissue refers to the presence of more glandular and fibrous tissue than fatty...

Read more

AmplifyBio Completes Acquisition of Intellectual Property to Offer Non-Viral Gene Editing Services for Clients

July 12, 2023 7:00 AM

WEST JEFFERSON, OH / ACCESSWIRE / July 12, 2023 / AmplifyBio, a leading service provider for the commercialization of advanced modality therapeutics, such as cell and gene therapies, today announced the successful acquisition of a cutting-edge intellectual property (IP) that, among other capabilities, will allow them to offer non-viral gene-editing services to clients. The move represents a significant milestone in AmplifyBio's mission to...

Read more

Abivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors

July 11, 2023 12:15 PM

PARIS, FRANCE / ACCESSWIRE / July 11, 2023 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces today the appointment of June Lee, M.D. and Troy Ignelzi as new independent members of the Abivax Board of Directors. June Lee and Troy Ignelzi replace Joy Amundson and...

Read more

Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge

July 11, 2023 7:00 AM

The Parkinson's disease market is expected to grow to $12.8 billion by 2028.LAS VEGAS, NV / ACCESSWIRE / July 11, 2023 / Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences' cannabinoid-based therapy for Parkinson's disease. The study has established dose...

Read more